Exchange: NASDAQ·Updated 07:59 PM EST
NAUT logo

NAUT Nautilus Biotechnology Inc

$2.12
$0.05
(2.30%)
Today
Closed $2.12
$0.01
(0.47%)
After Hours
Reported EarningsOct 27
Mkt Cap$270.03M
Vol6.26M

About NAUT

Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal M. Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.
38

Bearish Sentiment

How do you feel about NAUT?

Rebooter
$NAUT $QSI This assertion is so ridiculous it's difficult to know where to start. The TAM for mass spectrometry ALONE in 2026 is $7.9 billion to $8.3 billion and is projected to reach $13 billion by 2033. 70% of revenues in the proteomics category is reagents and consumables. Because NAUT's platform employs an affinity-based approach, reagents will be supplied to the end researcher by a third party. NAUT will only see a fraction of that revenue. In fact, this dependence on external suppliers is, per Nautilus CEO Patel, the reason the company is four years late (and counting) on Voyager. By contrast, QSI owns their supply chain and the recurring, high margin revenue that results from it. Understand, these two companies are not direct competitors. In some larger wet labs, the two platforms will sit side by side e.g. Voyager for upstream intake and Proteus for downstream analysis. I'm not sure what information you "parsed out", but your comment is flat out inaccurate.
12
TheNextWave
$NAUT saw the Pump & Dump interview with the Snake Oil Salesman on the right here. Trash 🗑️ looking for a divergence now Proteomics is the future & $QSI is “the ONLY horse in town”. Clear to anyone with a brain at this point. Pedigree included. Bargain bin as well. Catalysts approaching. I’ve researched NAUT enough to know there are too many lies. The pivot is just for stealing more money from investors after the August Flop Now they shamelessly worked with a Twitter Guru to pump the shares. Watch him move onto other tickers
2
5
Rebooter
$NAUT $QSI Anodei is right, but it will be AI analysis of proteomic SEQUENCING data that makes the cure of proteins-based diseases like the ones he named (and others, like diabetes) possible, just as genomic sequencing led to numerous therapeutic breakthroughs. Nautilus' Voyager platform is NOT a sequencing platform and will not produce unique data. It is an affinity-based assay platform. Think of it as a glorified catalog. Its purpose is to assist researchers in the identification of proteins, not in the sequencing and post-translational modification of proteins, which is where novel drug discovery and therapeutic breakthroughs will occur. Suggesting Nautilus will be responsible for these breakthroughs is like saying a paper clip cured cancer since a paper clip was in the room when the breakthrough was made.
8
Larry5500
$NAUT When Nature Methods published those incredible results, it placed NAUT in a unique place above the competition. Volume soon followed.
8
Rebooter
$NAUT $QSI Or here’s a better idea. Do the homework needed to understand the Affinity-based approach used by NAUT is already outdated relative to Next Generation Protein Sequencing (QSI) and cannot identify new drug targets and biomarkers i.e. the two biggest real-world needs of clinical researchers. The Affinity model is also highly reliant on third-party suppliers for reagents (the source of 70% of proteomics revenue) and, per the Nautilus CEO, is the reason the commercial launch of their platform is now four years (and counting) behind schedule. Most people haven’t done this homework and don’t understand these facts. So NAUT’s current market cap is higher than QSI’s. But any potential acquisition partner will certainly understand. ARK understood when they dumped their entire position in NAUT and became one of the largest shareholders in QSI. Merrill Lynch understood when they issued a SELL rating for NAUT because of the “competition”. Be patient, and know what you own.
8
Undercover_007
$NAUT $QSI $HIMS please guys! When you see this guy just sell everything! He sucks so much. Click on his name and look at his track record! Horrible
1
4
Omega_Proxy
$NAUT $QSI Please stop lying and or doing horrible research@TheNextWave Here is what actually happened with isilon systems and the ousted CEO: There is an important nuance regarding which CEO was implicated: The Implicated CEO (Steve Goldman): During the period of the fraud (around the company's 2006 IPO), Isilon’s CEO was Steve Goldman. Isilon's own internal Audit Committee investigation found evidence that former CEO Steve Goldman, former CFO Stuart Fuhlendorf, and the VP of North American sales had "participated directly" in the problematic side-deal transactions that forced the massive revenue restatement. Because of this finding, Goldman and Fuhlendorf were both abruptly ousted from the company in October 2007. [1, 2] The Stepping-In CEO (Sujal Patel): Sujal Patel was the original co-founder of Isilon Systems. When Steve Goldman was forced out due to the scandal in 2007, the board tapped Sujal Patel to step in as the new CEO to clean up the company and stabilize it.
2
Mrunkown
$NAUT one last thank to all the longs. Had a 6k short from 3.18 to 2.75. Also the 5 million short supply is gone I can't get anymore shares incase this things goes over 3 again. My guess is someone big plans to sell this trash.
6
gatortrixie
$NAUT they have a open s3 with a ATM Use caution here they said will raise equity cash
1
3
StonksCho
$NAUT shorties probably didn’t listen in on ER nor read transcript but run their mouths
1
2
BiotechSwings
$NAUT quietly ripped Friday. closed at 3.24, up about 25 percent from 2.60 on 14 million shares, and it's up 50 percent in five sessions into Tuesday's Q3 report. proteomics names don't usually move like this without a reason, and the earnings date is right there
5
mrdees
$NAUT earnings next week. Interesting to see what this does on Monday. Got a feeling this thing gaps up on Monday.
5
Omega_Proxy
$NAUT $QSI Reposting of this will continue until Stops posting on NAUT message board trying to get people to jump ship over to QSI
4
TheNextWave
$NAUT & then this scam shell company actually had the CEO on an interview with a Twitter Guru… This stock should be 50 Cents It’s not the real thing. Just talk.
1
1
TheNextWave
$NAUT you all should be ashamed of your Indian Scammer CEO who has engaged Twitter Guru Pump & Dump services & stole the Trade Thesis of QSI when it doesn’t even apply to NAUT scientifically. Now I know NAUT IS TRASH, QSI IS CASH
1
1
TheAdmiral
$NAUT quote CEO “Our seminal publication in Nature Methods highlights the unique biological insights that our technology can deliver. In addition, our proteoform expansion initiative is on-track, with early oncology assay results that demonstrate the performance we established with Tau is repeatable across additional targets. This repeatability is fundamental to our strategy of building a broad portfolio of proteoform assays, and the progress we are seeing reinforces our confidence in our technology, our development roadmap, and our planned instrument availability in the middle of 2027.”
4
TheAdmiral
Perfect $NAUT invests more and more in cancer akt1 assays - customer with deep pockets and Naut know it.
4
Dirk1969
$NAUT Nautilus Biotechnology Inc. 📈✅ Proteoforms represent the absolute future of precision medicine and biology. While genetics (DNA) provides the blueprint for life, proteoforms are the actual functional units that determine whether we remain healthy or become ill. A proteoform is a specific molecular variant of a protein, originating from a single gene through genetic variations, alternative RNA splicing, or post-translational modifications (such as phosphorylation or glycosylation). A single gene can thus give rise to hundreds of different proteoforms. The shift from measuring 'general proteins' to these specific proteoforms ushers in a revolutionary era.
4
VolumeSpreadAnalysis
$NAUT Price: $2.89 Volume: Above average Catalyst: Recent pipeline update on its oncology candidates has renewed speculative interest in the name. Resistance: $3.20 Support: $2.60 Bull case: A clean break above $3.20 on sustained volume could open the door toward $3.75. Bear case: Failure to hold $2.60 support risks a slide back toward $2.30. What I'm watching: Volume follow-through over the next few sessions to confirm whether buyers can defend the breakout. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio:
3
BellsUP2Stars
$NAUT old news below! It was done in September 2026. More fud to scare you! Science is brilliant, adding on dips.
3

Advertisement|Remove ads.